secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2022-04-20T23:59:59+00:00
Accession:  0000078003-22-000062
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer changes non-GAAP measure to include IPR&D costs; Q1 adj. income seen down ~$275M
--------------------------------------------------------------------------------

- Starting Q1 2022, acquired IPR&D costs (upfront/milestone payments, asset acquisitions) included in Adjusted income; prior periods recast.
- Expected Q1 2022 impact: Adjusted income reduced by ~$275M, Adjusted diluted EPS by ~$0.05.
- Acquired IPR&D expenses will appear as a separate income-statement line item going forward.
- FY guidance will include IPR&D costs for signed transactions through a defined date; excludes potential future deals.
- Recast GAAP-to-non-GAAP reconciliations for 2020 and 2021 to be posted on or before April 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800322000062/0000078003-22-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800322000062/pfe-20220420.htm
  HTML page:      https://secwatch.observer/filing/0000078003-22-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer